Background: Diagnosis of venous thromboembolic disease (deep venous thrombosis and pulmonary embolism) is often inaccurate because signs and symptoms are nonspecific. Numerous clinical management trials using D-dimer which is one of the coagulation markers have shown that it has a sufficient specificity to assist in the diagnosis of venous thromboembolic disease.
INTRODUCTION:
Deep venous thrombosis (DVT) and pulmonary embolism (PE) remain significant but preventable health care problems.
(1, 2) In absence of specific clinical manifestations, diagnosis of venous thromboembolic (VTE) disease is often inaccurate and it is based mainly upon clinical suspicion in patients at risk.
(1) Duplex ultrasound and other sophisticated imaging modalities remain essential for diagnosis, however, these procedures may not be readily available during off-hours making the availability of plasma markers for DVT more desirable.
(3) The most widely used test, D-dimer, is a fibrin degradation product detected in the blood after a blood clot is degraded by fibrinolysis and is useful to exclude the diagnosis of DVT due to its high sensitivity but its specificity is much lower. (4) The low specificity of D-dimer for diagnosis of VTE, especially in elderly, in addition to the increased plasma D-dimer concentrations in patients with extensive inflammation, wound healing, malignancy, and patients with liver disease make D-dimer primarily valuable when used in conjunction with clinical prediction scores.
(5, 6) Recent studies verified that, the application of age adjusted cutoff values for D-dimer tests substantially increases specificity without modifying sensitivity.
Other studies suggested that higher D-dimer cutoff values might increase its specificity improving its diagnostic accuracy and to reduce the use of venous duplex ultrasound scanning for ruling out DVT in their studied patients. (8) (9) (10) (11) This study was done to validate the utility of Ddimer as a diagnostic biomarker for DVT using Validation of New D-Dimer Cutoff… 364 a higher cutoff values which may improve the test specificity. Patients and method: In this retrospective chart review study, we reviewed the hospital records of all patients for whom D-dimer assay was done in King Abdul Aziz Specialist Hospital, Taif -Saudi Arabia from January 2011 to October 2013 after approval of the ethical committee. The study involved only the candidates who gave written consents to use the data in their hospital records. The study involved 141 individuals; 25 normal candidates, who were involved in other clinical trial and proved to be normal (with no clinical signs, symptoms or history of DVT) were chosen to serve as control group (Group I).Male to female ratio in group I was 1.3:1, their ages ranged from 20 -62 years, with a mean of 42.8 ± 11.66 years.
Group II included 61 patients who were positive for DVT by duplex ultrasound. Their ages ranged from 28 -65 years, with a mean of 44.04 ± 11.05 years with male to female ratio of 1.5:1. Patients of this group fulfilled the following inclusion criteria: their ages were 18 years or more, they had clinical manifestations suggestive of VTE and their diagnosis was confirmed to be a DVT by duplex ultrasound imaging.
Group III included 55 patients with symptoms of unilateral or bilateral leg pain or swelling but with negative duplex ultrasound for DVT. Their ages ranged from 28 -70 years, with a mean of 44.56 ± 11.66 years and male to female ratio of1.08:1. The hospital records of all subjects were revised for clinical history with special emphasis on smoking, obesity, medications, especially oral contraceptive pills, personal or family history of DVT, concurrent medical problems, history of cancer, serious extremity injuries and history of recent surgery in addition to the data of the clinical findings suggestive of DVT or / and pulmonary embolism. Reports of duplex ultrasound examination of the affected extremity were revised for each patient. Concerning patients' laboratory data, the following results were emphasized; Complete blood count (CBC), prothrombin time (P.T), activated partial thromboplastin time (aPTT) and D-dimer levels. figure 1 . There was a highly significant difference (p = 0.001) when we compared the D-dimer levels in group I and II (table 4). A highly significant difference (p = 0.001) was also found between controls (group I) and duplex negative patients (group III) as regards the biomarker levels (table 5). In comparing betweengroups II and III patients, a highly significant difference (p = 0.001was also verified (table 6). Receiver operator characteristic (ROC) curves (figures 2, A & B) were done to establish cutoff levels for the diagnosis of DVT, where a value of 0.92 mg/L of D-dimer that had 100% sensitivity, 100% specificity and 100% diagnostic accuracy was settled differentiating the control group (normal individuals) from the duplex positive group. Fifty five patients involved in this study (group III) were negative for DVT by duplex ultrasound; however, in a period of time ranging from 3 to 7 days, fifteen patients eventually developed positive criteria for DVT on scanning. Comparing patients who were negative for DVT by duplex ultrasound and did not develop thrombosis with patients of the same group who eventually developed thrombosis, Level of 2.81 mg/L for D-dimer was considered as a cut-off point that can differentiate patients who were duplex negative and free from thrombosis from those who eventually developed thrombosis with 77% sensitivity, 94% specificity, and 84% diagnostic accuracy.
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DISCUSSION:
The lack of subjective clinical symptoms and objective clinical signs for venous thromboembolism (VTE) makes the diagnosis complicated. (8) Currently, both imaging modalities and serology are utilized to establish the diagnosis of DVT, however, there is no single blood test exists alone to diagnose DVT and various plasma molecules are regarded as the biomarkers of DVT including D-dimer, P-selectin, Factor VIII, thrombin generation, inflammatory cytokines, microparticles, fibrin monomer, leukocyte count and so on.
(9) The sensitivity of D-dimer testing determines its safety in ruling out DVT; but its specificity is poor because fibrin is produced in a wide variety of conditions, such as patients with prolonged hospitalization, cancer, pregnancy, inflammation, infection and necrosis, so the negative predictive value of Ddimer is high, meanwhile, its positive predictive value is low. (10, 11) In this chart review study, there was no significant correlation between the laboratory variables of the studied groups, except for hemoglobin level which was significantly lower in both groups II ( patients who were positive for DVT by duplex scanning) and III ( patients who had symptoms of DVT but showed negative results on duplex ultrasound) if compared to the control group. The results of the studies of Ay et al. (12) and Fullmer (13) , were in accordance with our findings except for the hemoglobin where they reported no statistically significant difference in peak hemoglobin and hematocrit levels between patients with thrombosis and those without thrombosis. The patient records in the present study revealed that D-dimer level was significantly higher in duplex positive patients (Group II) than both control group (group I) and duplex negative patients (Group III). In agreement with our results, Rectenwald & his colleagues (11) , Tajanko et al. (14) , and Goldin& his group (15) , reported that D-dimer concentration was significantly higher in patient groups when compared to control group. The elevated levels of D-dimer in cases of DVT can be explained by the massive activation of the coagulation system leading to generation of fibrin which is cleaved by plasmin into high molecular weight fragments that are digested several times more by plasmin leading to the formation of Ddimer. (16) The diagnostic sensitivity and specificity of the different cutoff values for the D-dimer in the current study were done using receiver operator characteristic (ROC) curves. It was found that D-dimer cut-off point at 0.92 mg/L, showed 100% sensitivity and 100% specificity. These values were selected to differentiate between control subjects and patients with DVT whose diagnosis was documented by duplex, so that patients who have levels below these selected values can be safely regarded as DVT free and not given anticoagulant treatment. The results obtained by Goldinet al. (15) came in accordance with the findings of the present study. They found that D-dimer level of 0.9 mg/L was effective in predicting the presence of VTE among 734 studied patients.
The studies of Di Nisio et al.
; Legnani & his coworkers (17) and Ramaciotti et al. (18) supported the results of the current study; they declared that D-dimer value of 0.5 mg/L is a highly sensitive level that can safely exclude acute DVT without imaging. According to these cutoff levels, patients can be safely regarded as DVT free and not given thrombolytic therapy, thus sparing patients the unnecessary anticoagulation. It has been estimated that anticoagulant therapy is associated with 4% of all adverse events and 10% of potential adverse events in hospitalized patients. (17) The newly estimated cutoff point of Ddimer (2.81 mg/L) can be used to confirm the presence of DVT in patients who were negative for DVT by duplex ultrasound and did not develop thrombosis from patients of the same group who eventually developed thrombosis. Thus patients with D-dimer levels above this cutoff value could receive anticoagulation treatment even before confirming diagnosis by duplex ultrasound scanning or when it is unavailable. Similar results are obtained by Melina et al. (19) However, Yamaki and his colleagues (20) , recorded that D-dimer values using latex agglutination based assay at a cutoff of 1 mg/L have a sensitivity of 97% and specificity of 63% for exclusion of DVT concluding that the use of this cutoff value, would reduce the use of venous duplex ultrasound scanning by 44% for ruling out DVT in their studied patients. The difference of cutoff values between the studies may be related to the methodology. D-dimer assays that have been validated as tests for DVT vary in their sensitivity and specificity, partly because of differences in their accuracy and partly because of the cutoff 366 value they use to define normality, i.e., tradeoff between sensitivity and specificity.
(21) So, to reach an accepted diagnostic accuracy a new standardized cut-off value must be established for each test.
(8-11) Moreover Schouten et al.
, verified that, the application of age adjusted cut-off values for D-dimer tests substantially increases specificity without modifying sensitivity, thereby improving the clinical utility of D-dimer testing particularly in patients aged 50 or more. 
CONCLUSION
